Cancer screening company faces tough IPO test as market cools
Ammunition Life-tech has commercially launched five diagnostic tests for various types of cancer but could struggle to win over investors at an elevated valuation Key Takeaways: The company’s combined losses…
Relieved of ‘high-risk’ marker, New Horizon Health aims to break even next year
Encouraged by its fast-growing revenue last year, the cancer screening device maker believes its losses may end in 2023 Key Takeaways: New Horizon Health is expected to attract more investors…
Genecast Hopes for High IPO Valuation Despite Red Ink, Regulatory Risk
The maker of cancer diagnostics and testing products has made a second filing for a Hong Kong IPO, even as its industry faces regulatory risk due to the newness of…
Mega Genomics Eyes Hong Kong IPO To Ride Growing Popularity of Genetic Testing
The genetic testing company is looking to raise up to $33 million in a Hong Kong IPO as its services become popular in China Key Takeaways: Mega Genomics is looking…
FAST NEWS: Genetron’s Losses Grow as Covid Restrictions Hurt Business
The latest: Cancer-screening device maker Genetron Holdings Ltd. (GTH.US) said on Thursday its revenue grew 9.6% year-on-year in the fourth quarter to 146.9 million yuan ($23 million). Its loss for…
Recent Articles
RELATED ARTICLES
-
After winning global EV crown, BYD faces new challenge with profitability test
002594.SHE - Jacobio Pharma poised to turn a profit from precision cancer drugs
- Will yet another silicon carbide IPO test investor patience?
-
Lotus profit metrics improve, but road ahead still looks tough
LOT.US
- From friends to foes: Agile faces mounting troubles from former partner
